Entering text into the input field will update the search result below

CorMedix's CEO Discusses Q4 2013 Results - Earnings Call Transcript

Apr. 01, 2014 11:38 AM ETCorMedix Inc. (CRMD)1 Comment
SA Transcripts profile picture
SA Transcripts

CorMedix Inc. (NASDAQ:CRMD) Q4 2013 Earnings Conference Call April 1, 2014 9:00 AM ET


Randy Milby – Chief Executive Officer

Steven Lefkowitz – Chief Financial Officer (interim)

Tony Pfaffle – Chief Scientific Officer (acting)



Welcome to the CorMedix 2013 Year-End Results conference call. All lines have been placed on listen-only mode and the floor will be open for your questions following the presentation. Without further ado, it’s my pleasure to turn the floor over to your host, Mr. Randy Milby. Mr. Milby, the floor is yours.

Randy Milby

Good morning and welcome to the CorMedix 2013 Year-End conference call. With me in the room today is Steve Lefkowitz, our interim CFO, and Dr. Tony Pfaffle, our acting Chief Scientific Officer. I will start by providing you with an update on our ongoing operational progress before our interim CFO, Steve addresses our financial affairs.

CorMedix, a catheter care company, is a specialty pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of infectious diseases in both acute and chronic care settings. There is a large market need for Neutrolin because central line-associated bloodstream infections happen when a central line is not put in correctly or kept clean. This allows the line to become a freeway for germs to enter the body and cause serious bloodstream infections. Neutrolin contains taurolidine, an antibacterial, antifungal agent, and heparin, antithrombotic and anticoagulant.

Today, I will update you on four key catalysts of near and longer term growth for CorMedix: first, the launch of Neutrolin in the EU; second, plans for label expansion in the EU beyond the initial dialysis market; third, geographic expansion activities; and fourth, plans for U.S. marketing approval.

So first, successfully launched the product in Germany and the EU. We began to recognize sales in the fourth quarter

Recommended For You

Comments (1)

Not quite sure about the sell-off after the CC as well as the downward pressure a few days before the CC. The CC seems to indicate everything is on track including label expansion in Europe and trial to begin in the US. Additional countries have been targeted in Europe as well. CFO stated that cash reserve is enough for the co to be profitable. Not sure why the sell-off is all about. May be with the Wall Street's sudden turnaround, people want to take profits from selling CRMD now to move money to stocks with more immediate reward. Ready to buy more if it drops to $2 level.
To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.